BioTuesdays

Tag - PRQP

Stifel starts ProQR Therapeutics at buy; PT $20

Stifel initiated coverage of ProQR Therapeutics N.V. (NASDAQ:PRQP) with a “buy” rating and price target of $20. The stock finished at $6.22 on April 30. “As a clinical-stage company with demonstrated proof-of-concept...